| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.19 | 8e-09 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.15 | 5e-06 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.14 | 6e-06 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0006 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0008 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.17 | 0.001 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.096 | 0.003 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | -0.096 | 0.004 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | -0.096 | 0.004 |